Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project
CompanyDeals

Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial

Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership
CompanyDeals

Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership

Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration
CompanyDeals

Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration

Grand Pharmaceutical's STC3141 Sepsis Therapy Completes Phase II Patient Enrollment
CompanyDrug

Grand Pharmaceutical’s STC3141 Sepsis Therapy Completes Phase II Patient Enrollment

"Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors
CompanyDrug

Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors

Huahai Pharmaceutical's Adalimumab Biosimilar Accepted by China's CDE for Review
CompanyDrug

Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review

Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
CompanyDeals

Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress

Ascendis Pharma's TransCon hGH sBLA for Adult GHD Accepted by FDA
CompanyDrug

Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA

Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials
Company

Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials

Novo Nordisk's Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
CompanyDrug

Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication

Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
CompanyDrug

Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors